Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024

Sikander Ailawadhi, MD, discusses how emerging trends in targeted therapies, immunotherapies, and precision medicine presented at ASH 2024 are addressing unmet needs in the management of hematologic cancers and shaping future treatment strategies.

Now Viewing

EP: 1.Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024

EP: 2.Insights on CLL and SLL Treatment with BTK Inhibitors: Patient Preferences and Shared Decision-Making

EP: 3.Insights on Multiple Myeloma Treatment: Real-World Data on Survivorship Burden and Patient Preferences

EP: 4.Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients

EP: 5.Advancing Hematologic Care and the Future of Shared Decision-Making

Video content above is prompted by the following:

1. Coming into ASH 2024, what would you consider to be the largest unmet needs in the management of hematologic cancers?
2. What are the latest trends and innovations you have observed in the treatment and management of hematologic cancers leading up to and coming out of ASH 2024?

Related Videos

Related Content

Advertisement

May 29th 2025

CLL Linked With Worse COVID-19 Outcomes in Early Pandemic

Jared Kaltwasser

People with chronic lymphocytic leukemia (CLL) saw a 55% year-to-year increase in all-cause mortality in the early days of the pandemic, a Swedish study found.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

May 15th 2025

Novel AI-Based Score Could Pinpoint AF Risk in Patients With CLL on BTKis

Jared Kaltwasser

A significant number of patients taking Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) develop atrial fibrillation (AF).

May 1st 2025

Long-Term Data Show Favorable Survival Outcomes With G-Clb in Treatment-Naive CLL

AJMC Contributor

Participants in the CLL11 trial and a smaller group of patients followed after study completion showed improved overall survival with obinutuzumab and chlorambucil (G-Clb) compared with chemotherapy plus rituximab or chemotherapy alone for chronic lymphocytic leukemia (CLL).

May 1st 2025

Statins May Improve Survival Among Patients With CLL/SLL Receiving Ibrutinib

AJMC Contributor

The findings come from a review of 4 randomized clinical trials, which found that statin use at the start of treatment was associated with improved cancer-related survival, overall survival, and progression-free survival.

April 28th 2025

MRD-Guided Triplet Therapy Leads to Deep Remissions in R/R CLL

Jared Kaltwasser

Minimal residual disease (MRD)-guided triple therapy showed promising results for relapsed chronic lymphocytic leukemia (CLL), achieving high rates of undetectable disease and prolonged survival.

Related Content

Advertisement

May 29th 2025

CLL Linked With Worse COVID-19 Outcomes in Early Pandemic

Jared Kaltwasser

People with chronic lymphocytic leukemia (CLL) saw a 55% year-to-year increase in all-cause mortality in the early days of the pandemic, a Swedish study found.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

May 15th 2025

Novel AI-Based Score Could Pinpoint AF Risk in Patients With CLL on BTKis

Jared Kaltwasser

A significant number of patients taking Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) develop atrial fibrillation (AF).

May 1st 2025

Long-Term Data Show Favorable Survival Outcomes With G-Clb in Treatment-Naive CLL

AJMC Contributor

Participants in the CLL11 trial and a smaller group of patients followed after study completion showed improved overall survival with obinutuzumab and chlorambucil (G-Clb) compared with chemotherapy plus rituximab or chemotherapy alone for chronic lymphocytic leukemia (CLL).

May 1st 2025

Statins May Improve Survival Among Patients With CLL/SLL Receiving Ibrutinib

AJMC Contributor

The findings come from a review of 4 randomized clinical trials, which found that statin use at the start of treatment was associated with improved cancer-related survival, overall survival, and progression-free survival.

April 28th 2025

MRD-Guided Triplet Therapy Leads to Deep Remissions in R/R CLL

Jared Kaltwasser

Minimal residual disease (MRD)-guided triple therapy showed promising results for relapsed chronic lymphocytic leukemia (CLL), achieving high rates of undetectable disease and prolonged survival.